NASDAQ
25.09.25 | 21:59
1,800 US-Dollar
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.09. | ALX Oncology appoints board member Klencke as interim CMO | 1 | Investing.com | ||
| 12.09. | ALX Oncology CMO Alan Sandler Resigns; Appoints Board Member Barbara Klencke As Interim CMO | 1 | RTTNews | ||
| 12.09. | ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer | 192 | GlobeNewswire (Europe) | Dr. Barbara Klencke is an accomplished clinical leader with a distinguished track record in oncology drug development who currently serves on the Company's Board of Directors and will step down from... ► Artikel lesen | |
| ALX ONCOLOGY Aktie jetzt für 0€ handeln | |||||
| 12.09. | ALX ONCOLOGY HOLDINGS INC - 8-K, Current Report | 1 | SEC Filings | ||
| 19.08. | ALX Oncology doses first patient in phase 1 trial of EGFR cancer drug | 1 | Investing.com | ||
| 12.08. | ALX Oncology Q2 2025 slides: biomarker strategy shows promise as cash runway extends | 6 | Investing.com | ||
| 12.08. | ALX Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update | 316 | GlobeNewswire (Europe) | - Data from ASPEN-06 trial highlights CD47 expression as a key predictive biomarker of greater response to evorpacept in HER2+ Gastric Cancer; updated data to be presented at a medical conference... ► Artikel lesen | |
| 12.08. | ALX ONCOLOGY HOLDINGS INC - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 11.08. | ALX Oncology Holdings' Earnings: A Preview | 3 | Benzinga.com | ||
| 05.08. | ALX Oncology to Report Second Quarter 2025 Financial Results on August 12, 2025 | 1 | GlobeNewswire (USA) | ||
| 12.06. | ALX Oncology berichtet über Ergebnisse der Jahreshauptversammlung | 5 | Investing.com Deutsch | ||
| 12.06. | ALX ONCOLOGY HOLDINGS INC - 8-K, Current Report | 1 | SEC Filings | ||
| 27.05. | H.C. Wainwright maintains ALX Oncology stock Buy rating | 4 | Investing.com | ||
| 20.05. | ALX Oncology Highlights Differentiated Design, Preclinical Data and Development Plans for EGFR-Targeted ADC, ALX2004, in R&D Webcast Event | 174 | GlobeNewswire (Europe) | - A potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors, ALX2004 is uniquely designed with every component optimized to maximize the... ► Artikel lesen | |
| 13.05. | ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025 | 3 | GlobeNewswire (USA) | ||
| 08.05. | ALX ONCOLOGY HOLDINGS INC - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 08.05. | ALX Oncology GAAP EPS of -$0.58 misses by $0.10 | 2 | Seeking Alpha | ||
| 08.05. | ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update | 384 | GlobeNewswire (Europe) | Following announcement of prioritized development strategy for evorpacept in combination with anti-cancer antibodies at R&D Day in March, Company is on track to initiate Phase 2 ASPEN-Breast and Phase... ► Artikel lesen | |
| 08.05. | ALX ONCOLOGY HOLDINGS INC - 8-K, Current Report | 2 | SEC Filings | ||
| 07.05. | What's Next: ALX Oncology Holdings' Earnings Preview | 1 | Benzinga.com |
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 5,902 | -2,25 % | Puma Aktie: Neue Gerüchte - Aumovio, Circus, Evotec, Krones und Novo Nordisk im Marktbericht Börse Frankfurt | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| MODERNA | 21,060 | -0,28 % | Moderna-Aktie: Kurs heute im Minus (21,2677 €) | Am US-amerikanischen Aktienmarkt liegt die Aktie von Moderna zur Stunde im Minus. Der jüngste Kurs betrug 24,79 US-Dollar. Eine Verbilligung in Höhe von 1,09 US-Dollar müssen derzeit die Aktionäre von... ► Artikel lesen | |
| NOVAVAX | 7,137 | -0,28 % | Novavax Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
| CRISPR THERAPEUTICS | 52,00 | +0,97 % | CRISPR Therapeutics AG: CRISPR Therapeutics and Sirius Therapeutics Announce First Patient Dosed in Phase 2 Trial of SRSD107 for Thromboembolic Disorders in Europe | ZUG, Switzerland and BOSTON and SAN DIEGO and SHANGHAI, Sept. 22, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 2,040 | -1,92 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Second Quarter 2025 Financial Results and Recent Business Highlights | On track to submit Biologics License Application (BLA) for INO-3107 in 2H25, with the goal of file acceptance by year end
Completed design verification (DV) testing... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 13,825 | -2,98 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy | One dose of nex-z led to rapid, deep and durable TTR reductions, with mean reductions of at least 90% from baseline sustained through three yearsStabilization or improvement in disease-related clinical... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,498 | +5,06 % | Defence Therapeutics Inc.: Defence's Director, Strategy & Business Advisor Dr. Amie Phinney Discusses the Accum Platform on Money Talk Radio with Ellis Martin | Montreal, Quebec--(Newsfile Corp. - September 23, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in... ► Artikel lesen | |
| EDITAS MEDICINE | 2,706 | -2,45 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen | |
| TREVENA | 2,280 | -40,00 % | Hollywood Changemaker Oliver Trevena Joins Little Kitchen Academy as Investor | LOS ANGELES, CA / ACCESS Newswire / August 21, 2025 / Little Kitchen Academy (LKA), the premier Montessori-inspired cooking academy for children and teens ages 3-18, is proud to announce that Oliver... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 15,195 | 0,00 % | BMO upgrades Sarepta on Elevidys uptake, pipeline prospects | ||
| BIOMARIN PHARMACEUTICAL | 45,240 | +0,24 % | BioMarin Pharmaceutical Inc.: BioMarin Announces Positive Pivotal Phase 3 Data for PALYNZIQ (pegvaliase-pqpz) in Adolescents with Phenylketonuria at 15th International Congress of Inborn Errors of Metabolism | New data from Phase 3 PEGASUS study demonstrates a 49.7% decrease in mean blood Phe levels in adolescents aged 12-17 treated with PALYNZIQ
BioMarin's planned submission... ► Artikel lesen | |
| EXELIXIS | 33,210 | +0,09 % | Adagene Inc.: Adagene Expands SAFEbody Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate | SAN DIEGO and SUZHOU, China, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (Nasdaq: ADAG) today announced an amendment to the 2021 collaboration and license agreement with Exelixis.... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,034 | -0,75 % | PacBio enters high-throughput carrier screening market with expanded test suite | ||
| VAXART | 0,295 | -1,67 % | Vaxart, Inc.: Vaxart Announces Withdrawal of Reverse Stock Split Proposal | SOUTH SAN FRANCISCO, Calif., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) ("Vaxart" or the "Company"), a clinical-stage biotechnology company developing a range of oral recombinant... ► Artikel lesen | |
| NEUROCRINE BIOSCIENCES | 122,15 | +1,08 % | Neurocrine Reports Positive Data From Phase 2 Study Of Osavampator | WASHINGTON (dpa-AFX) - Neurocrine Biosciences, Inc. (NBIX) announced the presentation of new data from the Phase 2 SAVITRI study, which showed statistically significant and clinically meaningful... ► Artikel lesen |
Das Unternehmen ALX ONCOLOGY HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 1,800 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALX ONCOLOGY HOLDINGS INC finden Sie auf Wallstreet Online.